Altimmune Q1 net loss $22.6M; cash $535M; PERFORMA Phase 3 MASH trial initiation in H2 2026

Altimmune, Inc.

Net loss of $22.6M ($0.18 loss per share) vs $19.6M ($0.26) in Q1 2025; R&D $16.2M, G&A $8.1M.
Cash, equivalents and short-term investments $332M at Mar 31, 2026; $535M at Apr 30, 2026 after $225M public offering.
Initiation of PERFORMA Phase 3 MASH trial planned for H2 2026; topline RECLAIM Phase 2 AUD data expected Q3 2026; RESTORE Phase 2 ALD enrollment completion Q3 2026.
Pemvidutide received Breakthrough Therapy Designation for MASH; EASL presentations on May 28, 2026 including 48-week IMPACT data.

item 2.02item 9.01

Source: SEC EDGAR

accession 0001326190-26-000037

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.